切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (01) : 56 -60. doi: 10.3877/cma.j.issn.1674-1358.2018.01.011

所属专题： 总编推荐； 文献；

临床论著

慢性乙型肝炎患者外周血单核细胞中载脂蛋白B mRNA编辑酶催化多肽3G的表达及其临床意义
王建军1, 赵平1,†(), 靳雪原1, 程勇前1, 闫涛1, 刘红虹1, 吴亮1   
  1. 1. 100039　北京，解放军第302医院国际诊疗中心
  • 收稿日期:2017-03-08 出版日期:2018-02-15
  • 通信作者: 赵平
  • 基金资助:
    302医院院长基金(No. YNKT2014016); 国家十二五重大专项(No. 2013ZX10002001)

Expression and the clinical significance of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in peripheral blood mononuclear cell of patients with chronic hepatitis B

Jianjun Wang1, Ping Zhao1,†(), Xueyuan Jin1, Yongqian Cheng1, Tao Yan1, Honghong Liu1, Liang Wu1   

  1. 1. International Treatment Centre of Liver Diseases, The 302 Hospital of PLA, Beijing 100039, China
  • Received:2017-03-08 Published:2018-02-15
  • Corresponding author: Ping Zhao
  • About author:
    Corresponding author: Zhao Ping, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王建军, 赵平, 靳雪原, 程勇前, 闫涛, 刘红虹, 吴亮. 慢性乙型肝炎患者外周血单核细胞中载脂蛋白B mRNA编辑酶催化多肽3G的表达及其临床意义[J]. 中华实验和临床感染病杂志(电子版), 2018, 12(01): 56-60.

Jianjun Wang, Ping Zhao, Xueyuan Jin, Yongqian Cheng, Tao Yan, Honghong Liu, Liang Wu. Expression and the clinical significance of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in peripheral blood mononuclear cell of patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(01): 56-60.

目的

探讨载脂蛋白B mRNA编辑酶催化多肽3G感染的不同阶段及应用不同抗病毒药物治疗期间水平的差异，推测固有免疫在抗病毒治疗中的作用。

方法

选择应用聚乙二醇化干扰素α-2a抗病毒治疗的慢性乙型肝炎（CHB）患者30例，口服恩替卡韦抗病毒治疗的CHB患者30例，未应用抗病毒治疗的CHB患者和乙型肝炎肝硬化代偿期患者各20例；健康成人20例为健康对照。检测CHB患者不同感染阶段及应用不同抗病毒药物期间的HBV DNA载量、ALT水平，应用荧光定量RT-PCR分析外周血单个核细胞（PBMC）中APOBEC3G mRNA的含量。

结果

与健康成人比较，CHB、肝硬化患者应用恩替卡韦及干扰素抗病毒治疗期间，患者PBMC中APOBEC3G mRNA的含量分别升高1.4倍（t =－3.166、P = 0.003）、1.37倍（t =－2.206、P = 0.0335）、1.44倍（t =－3.381、P = 0.0014）和3.95倍（t =－4.790、P = 0.0002）。未应用抗病毒治疗的CHB患者血中的APOBEC3G mRNA的含量与应用恩替卡韦治疗患者差异无统计学意义（t =－0.242、P = 0.8097）。应用干扰素治疗的CHB患者PBMC中APOBEC3G mRNA的含量分别是未经治疗的CHB患者及应用恩替卡韦治疗患者的2.36倍（t = 4.085、P = 0.0002）和2.40倍（t = 4.9、P < 0.0001）。CHB炎患者ALT水平升高者PBMC中APOBEC3G mRNA的含量增高1.35倍，差异具有统计学意义（t = 2.667、P = 0.0112）。HBV DNA载量高低与A3G mRNA含量无关（F = 0.2124、P = 0.8871）。

结论

APOBEC3G在干扰素抗病毒治疗中起着重要作用。

关键词: 载脂蛋白B mRNA编辑酶催化多肽3G, 肝炎，乙型，慢性, 抗病毒治疗
Objective

To investigate the differences between the levels of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in different stages of HBV infection and during the different periods treated with different antiviral drugs, and to speculate on the role of innate immunity in antiviral therapy.

Methods

Total of 30 cases of chronic hepatitis B (CHB) who were treated with polyethylene glycol interferon alpha-2a and 30 patients treated with entecavir were selected, 20 patients with CHB and 20 patients with hepatitis B cirrhosis were selected; while 20 healthy adults collected as controls. The HBV DNA load and ALT levels were detected, and the level of APOBEC3G mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by fluorescence quantitative PCR.

Results

Compared with healthy cases, during the period of using entecavir and interferon of patients with CHB and liver cirrhosis and antiviral. The levels of APOBEC3G mRNA in patients’ PBMCs were increased by 1.4 times (t =-3.166, P = 0.003), 1.37 times (t =-2.206, P = 0.0335), 1.44 times (t =-3.381, P = 0.0014) and 3.95 times (t = -4.790, P = 0.0002) . There was no significant difference in the levels of APOBEC3G mRNA between the patients treated with entecavir and the patients without any treatment (t =-0.242, P = 0.8097). The levels of APOBEC3G mRNA in patients treated with interferon was 2.36 times (t = 4.085, P = 0.0002), 2.40 times (t = 4.9, P < 0.0001) as that in patients without any treatment and patients treated with entecavir, respectively. The levels of APOBEC3G mRNA in patients with high levels of ALT was 1.35 times higher than that of patients with normal level of ALT (t = 2.667, P = 0.0112). The levels of HBV DNA was not related to the content of APOBEC3G mRNA (F = 0.2124, P = 0.8871).

Conclusions

APOBEC3G plays an important role in the antiviral therapy of interferon.

Key words: Apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G), Chronic hepatitis B, Antiviral therapy
表1 各组患者与健康对照外周血PBMCs中APOBEC3G mRNA表达水平
组别 例数 PBMC A3G mRNA表达水平 t值 P值
健康对照 20 1
慢性乙型肝炎未治疗 20 1.4 ± 0.56 －3.166 0.0030
乙型肝炎肝硬化未治疗 20 1.37 ± 0.75 －2.206 0.0335
慢性乙型肝炎行核苷类似物治疗 30 1.44 ± 0.58 －3.381 0.0014
慢性乙型肝炎行pegIFN治疗 30 3.95 ± 2.745 －4.790 0.0002
表2 HBV DNA不同水平患者PBMC中APOBEC3G mRNA表达
HBV DNA水平（IU/ml） 例数 PBMC A3G mRNA表达
> 106 10 1.32 ± 0.48
103~106 22 1.45 ± 0.66
< 103 5 1.25 ± 0.47
< 40 3 1.38 ± 0.58
[1]
Mohamadkhani A, Pourdadash A, Tayebi S, et al. The potential role of APOBEC3G in limiting replication of hepatitis B virus[J]. Arab J Gastroenterol,2012,13(4):170-173.
[2]
Wang CX, Lu YQ, Qi P, et al. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeting retrovirus[J]. Virol J,2010,7:61.
[3]
Turelli P, Mangeat B, Jost S, et al. Inhibition of hepatitis B virus replication by APOBEC3G[J]. Science,2004,303(5665):1829.
[4]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△Ct Method[J]. Methods,2001,25(4):402-408.
[5]
Olson ME, Harris RS, Harki DA. APOBEC enzymes as targets for virus and cancer therapy[J]. Cell Chem Biol,2017,S2451-9456(17): 30388-30384.
[6]
Polevoda B, McDougall WM, Bennett RP, et al. Structural and functional assessment of APOBEC3G macromolecular complexes[J]. Methods,2016,107:10-22.
[7]
Nguyen DH, Gummuluru S, Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G[J]. J Virol,2007,81(9):4465-4472.
[8]
Nguyen DH, Hu J. Reverse transcriptase-and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids[J]. J Virol,2008,82(14):6852-6861.
[9]
Beggel B, Münk C, Däumer M, et al. Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B[J]. J Viral Hepat,2013,20(12):882-889.
[10]
Kitamura K, Wang Z, Chowdhury S, et al. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA[J]. PLoS Pathog,2013,9(5):e1003361
[11]
张伟，张旭照，方永明, 等. 胞嘧啶脱氨酶APOBEC3G可能通过G-A突变抑制乙型肝炎病毒的复制[J]. 中华微生物和免疫学杂志,2007,27(2):135-139.
[12]
Zhao D, Wang X, Lou G, et al. APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems[J]. Virus Res,2010,151(2):213-219.
[13]
Xu F, Song H, Li N, HBsAg blocks TYPE I IFN induced up-regulation of A3G through inhibition of STAT3[J]. Biochem Biophys Res Commun,2016,473(1):219-223.
[14]
Chen H, Wang LW, Huang YQ, et al. Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo[J]. Int J Mol Sci,2010,11(9):3501-3512.
[15]
Ezzikouri S, Kitab B, Rebbani K, et al. Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population[J]. J Viral Hepat,2013,20(10):678-686.
[16]
Meier MA, Suslov A, Ketterer S, et al. Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection[J]. J Viral Hepat,2017,24(8):662-671.
[17]
He XT, Xu HQ, Wang XM, et al. Association between polymorphisms of the APOBEC3G gene and chronic hepatitis B viral infection and hepatitis B virus-related hepatocellular carcinoma[J]. World J Gastroenterol,2017,23(2):232-241.
[18]
彭程，贺永文，郭春霞, 等. 慢性乙肝患者外周血单个核细胞APOBEC3GmRNA表达的水平及意义[J]. 寄生虫病与感染性疾病,2007,5(1):15-18.
[19]
陈辉，王鲁文，褚小刚, 等. 载脂蛋白BmRNA辑酶催化多肽样3G在不同慢性乙型肝炎患者中的表达及其细胞内定位[J]. 中华肝脏病杂志,2010,18(1):5-8
[20]
Song ZW, Ma YX, Fu BQ, et al. Altered mRNA levels of MOV10, A3G, and IFN-α in patients with chronic hepatitis B[J]. J Microbiol,2014,52(6):510-514.
[1] 施娜, 邱文倩, 何丹青, 张超学, 毛萍, 杨艳婷. 瞬时弹性成像评价慢性乙型肝炎患者抗病毒治疗的效果[J]. 中华医学超声杂志（电子版）, 2022, 19(05): 428-433.
[2] 高明茹, 董晓秋. 声脉冲辐射力成像联合瞬时弹性成像对炎性肝纤维化的诊断价值[J]. 中华医学超声杂志（电子版）, 2019, 16(07): 549-554.
[3] 马娟, 唐仕芳, 刘慧敏, 张娅琴, 邓义娟, 汪丽, 李力. 《乙型肝炎病毒母婴传播预防临床指南(2020)》更新要点解读[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(05): 516-526.
[4] 全敏, 闫改琴, 邢卉春. 可溶性Fas水平在慢性乙型肝炎患者抗病毒应答不佳优化治疗中的变化[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 16-23.
[5] 谢芳, 熊熙, 姚传霞, 孙浩男, 李平, 汪茂荣. 聚乙二醇化干扰素α-2b联合核苷（酸）类似物治疗低水平乙型肝炎病毒表面抗原慢性乙型肝炎患者的临床疗效及影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 247-253.
[6] 郑璇, 张宝, 李世龙, 张晓茹. 150例不同基因型慢性乙型肝炎患者逆转录聚合酶区耐药变异位点特征及耐药影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 82-89.
[7] 中国性病艾滋病防治协会学术委员会外科学组, 中华医学会热带病与寄生虫学分会外科学组, 国家传染病医学中心（北京）. 中国人类免疫缺陷病毒感染者围手术期抗病毒治疗专家共识（第二版）[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(05): 289-294.
[8] 钱舒然, 谭婧文, 王萌婕, 张思航, 杨镇英, 何越峰, 李晖. 致癌相关环状RNA在慢性乙型肝炎病毒感染者的表达及临床意义[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(02): 78-85.
[9] 徐鹏飞, 邓慧玲, 王小燕, 张瑜, 王军, 张玉凤, 唐甜甜, 袁娟, 宋鹤. 六例慢性乙型肝炎儿童患者抗病毒治疗短期疗效[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(06): 518-522.
[10] 李珺, 滕珈瑄, 田国保, 夏春花, 王笑灵, 董建平. 北京市海淀医院2017至2019年流感样病病原学监测及抗病毒治疗[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(03): 218-223.
[11] 施文娟, 张妍, 王兆勋, 万红. 91例丙氨酸氨基转移酶低于正常值上限二倍的慢性乙型肝炎患者肝组织病理特征与实验室指标的相关性[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(02): 138-143.
[12] 毛创杰, 胡蓉, 曾义岚, 张琼, 康信通. 替诺福韦酯对四川地区妊娠中期高HBV载量慢性乙型肝炎孕妇母婴阻断的疗效[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 485-490.
[13] 王金环, 于国英, 祖红梅, 杨秀兰, 郭建英, 丁瑞花, 庞玉花, 杨松. 三维显微定量超声在乙型肝炎肝硬化患者病情评价中的应用[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 472-477.
[14] 朱晨晨, 韩飞, 寿张飞. HCV阳性供肾移植单中心回顾性研究[J]. 中华移植杂志(电子版), 2023, 17(01): 47-53.
[15] 刀辰冉, 陈义发, 阿力木江·买合木提, 徐磊, 陈姚. S指数对符合米兰标准的肝癌合并慢性乙肝患者术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 274-278.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号